DrugPatentWatch Database Preview

Celgene Corp Company Profile

« Back to Dashboard

What is the competitive landscape for CELGENE CORP, and what generic alternatives to CELGENE CORP drugs are available?

CELGENE CORP has two approved drugs.

There are sixteen US patents protecting CELGENE CORP drugs.

There are one hundred and forty-two patent family members on CELGENE CORP drugs in thirty-seven countries and six supplementary protection certificates in six countries.

Summary for Celgene Corp

International Patents:	142
US Patents:	16
Tradenames:	2
Ingredients:	2
NDAs:	2
Drug Master File Entries:	4
Patent Litigation for Celgene Corp:	See patent lawsuits for Celgene Corp
PTAB Cases with Celgene Corp as patent owner:	See PTAB cases with Celgene Corp as patent owner

Drugs and US Patents for Celgene Corp

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes	9,018,243
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No	9,738,625			Y
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014		RX	Yes	No	7,893,101		Y	Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes	9,738,625			Y
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No	9,018,243
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No	9,512,107		Y	Y
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes	8,455,536

Expired US Patents for Celgene Corp

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014	6,020,358
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014	6,020,358
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014	6,020,358

Paragraph IV (Patent) Challenges for CELGENE CORP drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	10 mg, 20 mg and30 mg		2018-03-22

International Patents for Celgene Corp Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	03080049
Hong Kong	1215671
Spain	2637547
Spain	2635361
Japan	6411895
Singapore	10201602862R
South Korea	20050012722

Supplementary Protection Certificates for Celgene Corp Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2962690	2019C/008	Belgium		PRODUCT NAME: APREMILAST,OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/14/981 20150116
2962690	300994	Netherlands		PRODUCT NAME: APREMILAST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/981 20150116
2962690	LUC00125	Luxembourg		PRODUCT NAME: APREMILAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE:
2962690	37/2019	Austria		PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 (MITTEILUNG) 20150116
2962690	CA 2019 00033	Denmark		PRODUCT NAME: APREMILAST ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/981 20150116
2962690	122019000070	Germany		PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 20150115

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Celgene
• Celgene Corp